Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease
Hc. Meissner et al., Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease, ANTIM AG CH, 43(5), 1999, pp. 1183-1188
We conducted a multicenter, double-blind, placebo-controlled, randomized tr
ial of a humanized monoclonal antibody against a respiratory syncytial viru
s (RSV) fusion protein (SE 209763) to evaluate its safety, pharmacokinetics
, and fusion inhibition and neutralization titers. Forty-three infants who
were either delivered prematurely (less than or equal to 35 weeks' gestatio
n) or exhibited bronchopulmonary dysplasia were administered either single
or repeat (two doses, 8 weeks apart) intramuscular injections of SE 209763
at a concentration of 0.25, 1.25, 5.0, or 10.0 mg/kg or of a placebo. Four
of 229 adverse events were considered related to the study drug, including
purpura (n = 3) and thrombocytosis (n = 1). No subject developed a detectab
le level of anti-SE 209763 antibody. Approximately 1 week after administrat
ion of the second dose of SE 209763 at 10 mg/kg, the mean plasma concentrat
ion (n = 9) was 68.5 mu g/ml. The terminal half-life (T-1/2) determined by
noncompartmental analysis ranged from 22 to 50 days. The population pharmac
okinetics for SE 209763 following intramuscular administration was appropri
ately described by a one-compartment model with first-order input and elimi
nation. Higher values for clearance and volume of distribution at steady st
ate were observed for younger patients, with values decreasing to 0.143 (ml
/h)/kg and 161 mL/kg, respectively, by a mean age of 298 days (similar to 1
0 months). The mean T-1/2 of SE 209763 for the study population was 32.5 da
ys. No other factor (dose, weight, gender, race, premature birth, or bronch
opulmonary dysplasia) was observed to alter the population pharmacokinetics
of SE 209763 in this study of infants and young children. The mean neutral
ization titer on day 6 was 286, and the mean fusion inhibition titer was 36
. At least 57% of subjects dosed at 1.25 to 10.0 mg of SE 209763 per kg of
body weight who were seronegative at baseline experienced a fourfold or gre
ater increase in fusion inhibition titer. Nine RSV infections were document
ed during the 16-week course of the study; the numbers of RSV infections we
re similar for the different regimens, including the placebo. The doses of
SE 209763 studied may have been insufficient to confer protection against R
SV lower respiratory tract disease; these results suggest that additional t
rials using higher doses of monoclonal antibody for immunoprophylaxis shoul
d be considered.